Astrana Health, Inc. (ASTH)
NASDAQ: ASTH · Real-Time Price · USD
22.07
-0.72 (-3.16%)
Dec 5, 2025, 4:00 PM EST - Market closed
Astrana Health Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Astrana Health stock ranges from a low of $26 to a high of $56. The average analyst price target of $43 forecasts a 94.83% increase in the stock price over the next year.
Price Target: $43.00 (+94.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Astrana Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $44 → $37 | Strong Buy | Maintains | $44 → $37 | +67.65% | Nov 25, 2025 |
| Barclays | Barclays | Hold Maintains $36 → $26 | Hold | Maintains | $36 → $26 | +17.81% | Nov 24, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $40 → $35 | Strong Buy | Maintains | $40 → $35 | +58.59% | Nov 10, 2025 |
| BTIG | BTIG | Strong Buy Maintains $50 → $45 | Strong Buy | Maintains | $50 → $45 | +103.90% | Nov 7, 2025 |
| Barclays | Barclays | Hold Initiates $36 | Hold | Initiates | $36 | +63.12% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
3.22B
from 2.03B
Increased by 58.37%
Revenue Next Year
4.04B
from 3.22B
Increased by 25.48%
EPS This Year
0.60
from 0.90
Decreased by -33.25%
EPS Next Year
1.38
from 0.60
Increased by 129.03%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.3B | 4.4B | ||||
| Avg | 3.2B | 4.0B | ||||
| Low | 3.1B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 63.6% | 36.8% | ||||
| Avg | 58.4% | 25.5% | ||||
| Low | 51.0% | 8.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.30 | 2.23 | |
| Avg | 0.60 | 1.38 | |
| Low | 0.35 | 0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 44.7% | 270.5% | |
| Avg | -33.2% | 129.0% | |
| Low | -60.8% | -95.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.